查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1451397

2024-2032 年按来源、产品、疾病、製造和地区分類的生物製品市场报告

Biologics Market Report by Source, Product, Disease, Manufacturing, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3个工作天内

价格

2023年全球生物製品市场规模达3,496亿美元。展望未来， IMARC Group预计到2032年市场规模将达到6,995亿美元，2024-2032年复合年增长率（CAGR）为7.8%。慢性病盛行率不断上升，需要更有效的治疗方案，不断的技术进步促进了越来越有针对性的疗法的开发，以及先进的药物传输系统的出现，这些都是推动市场发展的一些因素。

生物製剂是源自活细胞的复杂分子，用于诊断、治疗和预防疾病。这些分子与小分子药物有着根本的不同，不仅在尺寸上，而且在结构的复杂性上。这些药物解决方案具有高度特异性的特点，经过专门设计，可与人体内的特定成分（例如细胞和蛋白质）相互作用。这一独特的属性使它们能够更精确地针对疾病途径，提供更高的疗效潜力，同时最大限度地减少副作用。其工作机制通常涉及透过阻断或增强天然分子的活性来调节生物途径，以恢復生理功能或消除病理因子。

这些复杂分子的全球市场主要是由慢性病盛行率上升所推动的，这需要更有效的治疗选择。与此一致的是，不断的技术进步促进了越来越有针对性的疗法的开发，这反过来又为市场提供了动力。此外，不断扩大的医疗保健预算导致对先进治疗方案的持续需求，成为重要的成长诱导因素。除此之外，向个人化医疗的转变导致客製化疗法的采用率更高，从而进一步扩大了市场。促进市场成长的其他一些因素包括知情且受过教育的患者基础、人工智慧在药物发现中的优化作用、生物製药实体之间的策略合作，以及随着非专利版本变得更容易被更大的人使用而出现的生物相似药的出现。人口。

生物製品市场趋势/驱动因素：

标靶治疗持续创新

复杂分子市场的一个重要驱动力是标靶治疗的持续创新。这些疗法旨在专门作用于某些导致疾病的细胞或分子，从而提高治疗效果，同时最大限度地减少副作用。鑑于癌症和自体免疫疾病等疾病的严重性，标靶治疗提供了一种新颖有效的治疗途径。广泛的科学研究使人们能够在分子层面上了解疾病机制，为比传统方法更有效、毒性更小的专门治疗方法铺平了道路。随着研发投资的增加，加上对个人化医疗的高度关注，这些标靶疗法有望成为主流。它们的推出和随后的成功可以大大提高对复杂分子的需求，从而成为市场的关键驱动力。

先进药物输送系统的出现

药物输送系统在医疗保健中发挥越来越重要的作用，通常决定复杂分子治疗的有效性和患者依从性。该领域的创新有多种形式，从控释机製到基于奈米技术的输送系统。这些进步使患者更容易坚持治疗方案，进而改善临床结果。例如，较新的输送系统可能会以每週甚至每月剂量取代每日註射，大大提高患者的便利性和继续治疗的意愿。大量投资正在流入这些技术的研究和开发，目的是最大限度地提高复杂分子的治疗效果。药物输送系统的这些进步极大地增强了市场的弹性和成长潜力，满足了对更有效和对患者友好的治疗选择的需求。

监管变化和协调

长期以来，对于医疗保健产业的公司来说，穿越迷宫般的监管环境一直是一项艰鉅的挑战。然而，当前监管协调的趋势正在简化这一复杂的情况。透过不同国家统一或相互认可的审批流程，市场准入障碍大大降低。这意味着新产品和现有产品可以比以前更快地覆盖更广泛的患者群体。其影响是多方面的：不仅加快了向患者提供这些创新疗法的速度，而且这些产品的地理覆盖范围也显着扩大。透过加速审批和扩大市场准入，这种有利的监管实践协调正在推动复杂生物分子全球市场的大幅持续成长。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球生物製品市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依来源

  • 微生物
    • 市场走向
    • 市场预测
  • 哺乳动物
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 7 章：市场区隔：依产品

  • 单株抗体
    • 市场走向
    • 市场预测
  • 疫苗
    • 市场走向
    • 市场预测
  • 重组蛋白
    • 市场走向
    • 市场预测
  • 反义、RNAi 和分子治疗
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 8 章：市场区隔：依疾病分类

  • 肿瘤学
    • 市场走向
    • 市场预测
  • 免疫系统疾病
    • 市场走向
    • 市场预测
  • 心血管疾病
    • 市场走向
    • 市场预测
  • 血液系统疾病
    • 市场走向
    • 市场预测
  • 其他的
    • 市场走向
    • 市场预测

第 9 章：市场区隔：依製造业划分

  • 外包
    • 市场走向
    • 市场预测
  • 内部
    • 市场走向
    • 市场预测

第 10 章：市场区隔：按地区

  • 北美洲
    • 美国
      • 市场走向
      • 市场预测
    • 加拿大
      • 市场走向
      • 市场预测
  • 亚太
    • 中国
      • 市场走向
      • 市场预测
    • 日本
      • 市场走向
      • 市场预测
    • 印度
      • 市场走向
      • 市场预测
    • 韩国
      • 市场走向
      • 市场预测
    • 澳洲
      • 市场走向
      • 市场预测
    • 印尼
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 欧洲
    • 德国
      • 市场走向
      • 市场预测
    • 法国
      • 市场走向
      • 市场预测
    • 英国
      • 市场走向
      • 市场预测
    • 义大利
      • 市场走向
      • 市场预测
    • 西班牙
      • 市场走向
      • 市场预测
    • 俄罗斯
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 拉丁美洲
    • 巴西
      • 市场走向
      • 市场预测
    • 墨西哥
      • 市场走向
      • 市场预测
    • 其他的
      • 市场走向
      • 市场预测
  • 中东和非洲
    • 市场走向
    • 市场细分：按国家/地区
    • 市场预测

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第15章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca plc
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
Product Code: SR112024A3883

The global biologics market size reached US$ 349.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 699.5 Billion by 2032, exhibiting a growth rate (CAGR) of 7.8% during 2024-2032. The rising prevalence of chronic diseases that necessitate more effective treatment options, continual technological advancements facilitating the development of increasingly targeted therapies, and the emergence of advanced drug delivery systems represent some of the factors that are propelling the market.

Biologics are complex molecules derived from living cells, which are used to diagnose, treat, and prevent diseases. These molecules are fundamentally different from small-molecule drugs, not only in terms of size but also in the intricacy of their structure. Characterized by a high degree of specificity, these medicinal solutions are tailored to interact with specific components within the human body, such as cells and proteins. This unique attribute enables them to target disease pathways more precisely, offering a higher potential for efficacy while minimizing side effects. The working mechanism often involves the modulation of biological pathways, either by blocking or enhancing the activity of naturally occurring molecules, to restore physiological function or eliminate pathological agents.

The global market for these complex molecules is primarily driven by the rising prevalence of chronic diseases that necessitate more effective treatment options. In line with this, continual technological advancements facilitating the development of increasingly targeted therapies, which in turn is providing an impetus to the market. Moreover, expanding healthcare budgets are resulting in a sustained demand for advanced therapeutic options, acting as a significant growth-inducing factor. In addition to this, the shift toward personalized medicine is leading to higher adoption rates of tailored therapies, thus expanding the market further. Some of the other factors contributing to the market's growth include an informed and educated patient base, the optimizing role of artificial intelligence in drug discovery, strategic collaborations between biopharmaceutical entities, and the emergence of biosimilars as off-patent versions become more accessible to a larger population.

Biologics Market Trends/Drivers:

Continual innovations in targeted therapies

A significant driver in the market for complex molecules is the continuous innovation in targeted therapies. These are therapies designed to specifically act on certain cells or molecules responsible for disease, thus increasing treatment effectiveness while minimizing side effects. Given the critical nature of diseases like cancer and autoimmune disorders, targeted therapies offer a novel and effective avenue for treatment. Extensive scientific research has enabled the understanding of disease mechanisms at the molecular level, paving the way for specialized treatments that are more effective and less toxic than traditional approaches. With increasing investments in research and development, coupled with a heightened focus on personalized medicine, these targeted therapies are poised to become mainstream. Their introduction and subsequent success can substantially elevate the demand for complex molecules, thus serving as a pivotal driver for the market.

The emergence of advanced drug delivery systems

Drug delivery systems play an increasingly crucial role in healthcare, often determining the effectiveness and patient compliance for complex molecular treatments. Innovation in this sector comes in various forms, from controlled-release mechanisms to nanotechnology-based delivery systems. Such advancements make it easier for patients to adhere to their treatment regimens, thereby improving clinical outcomes. For instance, newer delivery systems might replace daily injections with weekly or even monthly doses, substantially enhancing patient convenience and willingness to continue treatment. Significant investments are flowing into the research and development of these technologies, with the aim to maximize the therapeutic effectiveness of complex molecules. These advances in drug delivery systems are contributing immensely to the market's resilience and growth potential, fulfilling a demand for more efficient and patient-friendly therapeutic options.

Regulatory changes and harmonization

Navigating through the labyrinthine regulatory environments has long been a daunting challenge for companies in the healthcare sector. However, the current trend toward regulatory harmonization is simplifying this complex landscape. With unified or mutually recognized approval processes across different countries, market entry barriers are substantially reduced. This means that new and existing products can reach a wider patient base much faster than before. The implications are manifold: not only is there an accelerated pace at which these innovative therapies are made available to patients, but there is also a significant expansion in the geographic reach of these products. This favorable alignment of regulatory practices, by expediting approvals and broadening market access, is driving substantial and sustained growth in the global market for complex biologics molecules.

Biologics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global biologics market report, along with forecasts at the global, regional and country levels for 2024-2032. Our report has categorized the market based on source, product, disease, and manufacturing.

Breakup by Source:

Microbial

Mammalian

Others

Microbial accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the source. This includes microbial, mammalian, and others. According to the report, microbial represented the largest segment.

The microbial segment in the global market is mainly driven by its cost-effectiveness and shorter production times compared to mammalian cell cultures. The ability of microbial systems to produce large quantities of proteins makes them an attractive option for the mass production of vaccines and insulin. Moreover, advancements in microbial fermentation technologies are making it easier to produce complex proteins. Furthermore, a wide range of approved microbial-based products and a robust pipeline of microbial-based therapies are contributing to the growth of this segment.

On the other hand, the mammalian cell culture segment is particularly suited for the production of complex biologics that require post-translational modifications. Though costlier and more time-consuming than microbial systems, mammalian cell culture remains critical for certain high-value biologics, like monoclonal antibodies. Advances in cell line development and culture methods are contributing to increased yields and efficiency. Given the specific advantages, the mammalian segment continues to maintain a substantial share in the market.

Breakup by Product:

Monoclonal Antibodies

Vaccines

Recombinant Proteins

Antisense, RNAi and Molecular Therapy

Others

Monoclonal antibodies represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the product. This includes monoclonal antibodies, vaccines, recombinant proteins, antisense, RNAi and molecular therapy, and others. According to the report, monoclonal antibodies represented the largest segment.

The monoclonal antibodies (mAbs) segment is increasingly prominent due to their specificity in targeting a wide array of diseases including cancers, autoimmune disorders, and infections. Technological advancements in antibody engineering and hybridoma technologies have allowed for the development of highly specific and potent mAbs. Additionally, the growing number of FDA approvals for monoclonal antibodies further fuels this segment. The capacity for personalized treatment options using monoclonal antibodies also adds to its robust market potential.

On the other hand, the segments comprising vaccines, recombinant proteins, antisense RNAi, and molecular therapy, is primarily fueled by advances in genetic engineering and biotechnology. These approaches offer new avenues for treating a variety of diseases that are not adequately addressed by existing therapies. Investments in R&D are contributing to the growth of this segment, along with a growing understanding of the mechanisms behind these therapies. A robust pipeline of products in clinical trials indicates promising future prospects for these segments.

Breakup by Disease:

Oncology

Immunological Disorders

Cardiovascular Disorders

Hematological Disorders

Others

Oncology accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the disease. This includes oncology, immunological disorders, cardiovascular disorders, hematological disorders, and others. According to the report, oncology represented the largest segment.

The oncology segment in the global market is driven by the high prevalence of cancer worldwide and an aging population more susceptible to this disease. Advancements in genomics have facilitated the development of targeted therapies for various types of cancer. The growing awareness about personalized medicine and targeted therapy in cancer treatment is also propelling this segment forward. Moreover, a strong pipeline of oncology biologics in clinical trials indicates future market growth.

On the other hand, the minor segments consisting of immunological, cardiovascular, and hematological disorders is driven by increasing incidence rates and a lack of effective treatments in some cases. Emerging biologics offer novel methods for treating these conditions, including monoclonal antibodies and recombinant proteins. The growing awareness of these innovative treatments among healthcare professionals and patients is also contributing to these segments. A strong pipeline of therapies targeting these disorders is indicative of potential growth.

Breakup by Manufacturing:

Outsourced

In-House

In-house represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the manufacturing. This includes outsourced and in-house. According to the report, in-house represented the largest segment.

The in-house segment benefits from complete control over the research, development, and manufacturing processes. Organizations are increasingly preferring in-house production to protect intellectual property rights and proprietary technologies. In-house facilities also allow for quicker adaptations to market changes and more effective implementation of quality controls. The capacity for more integrated and streamlined operations contributes to the growth of the in-house segment in the global biologics market.

On the other hand, outsourcing is an increasingly common practice due to the high costs and complexities associated with biologics production. Organizations are utilizing contract manufacturing organizations (CMOs) to lower operational costs and accelerate time-to-market. Outsourcing also allows companies to focus on core competencies like R&D while leaving production to specialized firms. Thus, the outsourced segment is seeing consistent growth in the biologics market.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest biologics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America dominates the global biologics market, primarily due to the presence of a well-established healthcare infrastructure and significant investments in biopharmaceutical research. The region is home to numerous leading biopharmaceutical companies and research institutions that drive innovation, which is creating a positive outlook for the market.

In addition to this, favorable regulatory support in the form of fast-track approvals for biologics and various financial incentives for extensive research and development (R&D) activities are also contributing to the market growth. Moreover, rising patient awareness and willingness to adopt new therapies are further fueling the demand for biologics in North America.

Furthermore, the U.S. is the largest market within the region, which is majorly buoyed by high healthcare spending, broad insurance coverage, and an increase in chronic and lifestyle-related diseases.

Competitive Landscape:

Key players in the global biologics market are aggressively focusing on innovation and research & development (R&D) activities. They are continually expanding their product pipelines to include advanced therapies in oncology, immunology, and other therapeutic areas. To meet stringent regulatory requirements, companies are investing significantly in state-of-the-art manufacturing facilities that adhere to good manufacturing practices. Collaborative agreements with academic institutions are being initiated for acquiring novel technologies. Through mergers and acquisitions, these organizations are consolidating their market presence. Strategic partnerships with smaller biotech companies are enabling the leveraging of unique skill sets and technologies. Furthermore, market leaders are engaging in patient access programs to facilitate the affordability of biologics.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AbbVie Inc.

Amgen Inc.

AstraZeneca plc

F. Hoffmann-La Roche Ltd

GlaxoSmithKline plc

Johnson & Johnson

Merck KGaA

Novartis AG

Pfizer Inc.

Sanofi

Recent Developments:

In August 2023, AbbVie Inc. announced that the European Commission has approved AQUIPTA (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month. The approval makes AQUIPTA the first and only once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) treatment in the European Union for the preventive treatment of both chronic and episodic migraine.

In September 2023, Amgen announced that it has reached a consent order agreement with the Federal Trade Commission, resolving a pending lawsuit and paving the way for its acquisition of Horizon Therapeutics. The companies anticipate finalizing the acquisition in early Q4 2023, focusing on serving patients with rare diseases.

In August 2023, AstraZeneca plc announced that Japan's Ministry of Health, Labour and Welfare has approved the expanded use of Soliris (eculizumab) for treating pediatric patients with generalized myasthenia gravis who are resistant to other therapies. The approval follows positive outcomes from a Phase III trial, making Soliris the first targeted therapy for this condition in children and adolescents in Japan.

Key Questions Answered in This Report

  • 1. What was the size of the global biologics market in 2023?
  • 2. What is the expected growth rate of the global biologics market during 2024-2032?
  • 3. What are the key factors driving the global biologics market?
  • 4. What has been the impact of COVID-19 on the global biologics market?
  • 5. What is the breakup of the global biologics market based on the source?
  • 6. What is the breakup of the global biologics market based on the product?
  • 7. What is the breakup of the global biologics market based on the disease?
  • 8. What is the breakup of the global biologics market based on the manufacturing?
  • 9. What are the key regions in the global biologics market?
  • 10. Who are the key players/companies in the global biologics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Biologics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Source

  • 6.1 Microbial
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Mammalian
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Monoclonal Antibodies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Vaccines
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Recombinant Proteins
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Antisense, RNAi and Molecular Therapy
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Disease

  • 8.1 Oncology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Immunological Disorders
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Cardiovascular Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Hematological Disorders
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Manufacturing

  • 9.1 Outsourced
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 In-House
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AbbVie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Amgen Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 AstraZeneca plc
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 F. Hoffmann-La Roche Ltd
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 SWOT Analysis
    • 15.3.5 GlaxoSmithKline plc
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Johnson & Johnson
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Merck KGaA
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Novartis AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Pfizer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sanofi
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Biologics Market: Major Drivers and Challenges
  • Figure 2: Global: Biologics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Biologics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Biologics Market: Breakup by Source (in %), 2023
  • Figure 5: Global: Biologics Market: Breakup by Product (in %), 2023
  • Figure 6: Global: Biologics Market: Breakup by Disease (in %), 2023
  • Figure 7: Global: Biologics Market: Breakup by Manufacturing (in %), 2023
  • Figure 8: Global: Biologics Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Biologics (Microbial) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Biologics (Microbial) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Biologics (Mammalian) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Biologics (Mammalian) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Biologics (Other Sources) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Biologics (Other Sources) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Biologics (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Biologics (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Biologics (Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Biologics (Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Biologics (Recombinant Proteins) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Biologics (Recombinant Proteins) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Biologics (Antisense, RNAi and Molecular Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Biologics (Antisense, RNAi and Molecular Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Biologics (Other Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Biologics (Other Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Biologics (Oncology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Biologics (Oncology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Biologics (Immunological Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Biologics (Immunological Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Biologics (Cardiovascular Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Biologics (Cardiovascular Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Biologics (Hematological Disorders) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Biologics (Hematological Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Biologics (Other Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Biologics (Other Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Biologics (Outsourced) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Biologics (Outsourced) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Biologics (In-House) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Biologics (In-House) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: North America: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: North America: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: United States: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: United States: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Canada: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Canada: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Asia-Pacific: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Asia-Pacific: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: China: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: China: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Japan: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Japan: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: India: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: India: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: South Korea: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: South Korea: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Australia: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Australia: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Indonesia: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Indonesia: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Others: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Others: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Europe: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Europe: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Germany: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Germany: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: France: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: France: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: United Kingdom: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: United Kingdom: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Italy: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Italy: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Spain: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Spain: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Russia: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Russia: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Others: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Others: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Latin America: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Latin America: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Brazil: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Brazil: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Mexico: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Mexico: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Others: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Others: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Middle East and Africa: Biologics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Middle East and Africa: Biologics Market: Breakup by Country (in %), 2023
  • Figure 87: Middle East and Africa: Biologics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 88: Global: Biologics Industry: SWOT Analysis
  • Figure 89: Global: Biologics Industry: Value Chain Analysis
  • Figure 90: Global: Biologics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Biologics Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Biologics Market Forecast: Breakup by Source (in Million US$), 2024-2032
  • Table 3: Global: Biologics Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 4: Global: Biologics Market Forecast: Breakup by Disease (in Million US$), 2024-2032
  • Table 5: Global: Biologics Market Forecast: Breakup by Manufacturing (in Million US$), 2024-2032
  • Table 6: Global: Biologics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Biologics Market: Competitive Structure
  • Table 8: Global: Biologics Market: Key Players